Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 28, 2015; 21(40): 11469-11480
Published online Oct 28, 2015. doi: 10.3748/wjg.v21.i40.11469
Published online Oct 28, 2015. doi: 10.3748/wjg.v21.i40.11469
Table 1 Studies investigating the correlation between faecal calprotectin concentrations and endoscopic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Endoscopic index used | Endoscopic indexcut off | Faecal calprotectincut off (μg/g) | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | |||||
Crohn’s disease studies | ||||||||||||
Falvey et al[46] | 59 | Adults | SES-CD | ≤ 3 | 125 | 71% | 71% | 85% | 50% | 0.55% | < 0.0001 | |
200 | 60% | 79% | 88% | 45% | ||||||||
Lobatón et al[51] | 85 | Adults | CDEIS | < 3 | 274 ELISA | 77% | 97% | 75% | 98% | 0.784% | < 0.001 | |
< 3 | 272 QPOC | 79% | 97% | 76% | 98% | 0.722% | < 0.001 | |||||
0 | 262 ELISA | 75% | 76% | |||||||||
0 | 200 QPOC | 75% | 77% | |||||||||
Nancey et al[45] | 78 | Adults | SES-CD | ≤ 2 | 250 | 71% | 78% | 79% | 71% | 0.53% | < 0.0001 | |
100 | 88% | 38% | 62% | 73% | ||||||||
D’Haens et al[47] | 87 | Adults | CDEIS | ≤ 3 | < 250 | 94.1% | 62.2% | 48.5% | 96.6% | 0.419% | < 0.001 | |
SES-CD | 0 | < 250 | 51.6% | 82.6% | 89.2% | 38% | 0.49% | < 0.001 | ||||
af Björkesten et al[15] | 64 | Adults | SES-CD | ≤ 2 | < 100 | 81% | 74% | - | - | 0.56% | < 0.001 | |
< 94 | 84% | 74% | - | - | ||||||||
SES-CD | 0 | < 94 | 82% | 78% | - | - | ||||||
Aomatsu et al[16] | 18 | Paediatrics | SES-CD | 0 | 100 | 94.7% | 50% | 87.8% | 71.4% | 0.76% | < 0.01 | |
150 | 94.7% | 50% | 87.8% | 71.4% | ||||||||
Sipponen et al[17] | 19 | Adults | SES-CD | ≤ 2 | < 100 | - | 80% | - | - | - | - | |
Schoepfer et al[21] | 122 | Adults | SES-CD | ≤ 3 | < 50 | 89% | 58% | 89% | 61% | 0.75% | < 0.01 | |
< 70 | 89% | 72% | 88% | 76% | ||||||||
Langhorst et al[23] | 43 | Adults | SES-CD | > 6 | 100% | 30% | 82.5% | 100% | 0.35% | < 0.05 | ||
> 48 | 81.8% | 80% | 93.1% | 57.1% | ||||||||
Schoepfer et al[22] | 36 | Adults | SES-CD | ≤ 19 | 50 | - | - | - | - | - | < 0.0001 | |
Sipponen et al[18] | 61 | Adults | SES-CD (total) | ≤ 3 | < 100 | - | - | - | - | 0.662% | < 0.001 | |
SES-CD (colon) | ≤ 3 | < 100 | - | - | - | - | 0.642% | < 0.001 | ||||
SES-CD (ileal) | ≤ 3 | < 100 | - | - | - | - | 0.317% | > 0.05 | ||||
Sipponen et al[19] | 15 | Adults | CDEIS | ≤ 2 | < 200 | 87% | 100% | 100% | 70% | 0.831% | < 0.001 | |
Sipponen et al[20] | 77 | Adults | CDEIS | ≤ 2 | < 50 | 91% | 44% | 76% | 73% | 0.729% | < 0.001 | |
< 100 | 81% | 69% | 84% | 66% | ||||||||
< 200 | 70% | 92% | 94% | 61% | ||||||||
Jones et al[24] | 164 | Adults | SES-CD | ≤ 6 | ≤ 50 | - | - | - | - | 0.45% | < 0.05 | |
Denis et al[25] | 28 | Adults | CDEIS | ≤ 5 | < 50 | - | - | - | - | - | 0.57 | |
Schoepfer et al[26] | 24 | Adults | SES-CD | ≤ 19 | < 50 | - | - | - | - | - | 0.0001 | |
D'Incà et al[28] | 31 | Adults | SES-CD | > 80 | - | - | - | - | 0.48% | 0.008 | ||
Mixed inflammatory bowel disease population studies | ||||||||||||
Molander et al[29] | 183 | 69 | Mixed | SES-CD; Mayo | ≤ 2; ≤ 1 | < 100 | - | - | - | 72% | - | < 0.0001 |
Vieira et al[30] | 38 | 40 | Adults | CDEIS; Mayo | ≤ 2; ≤ 2 | > 200.01 | 88.6% | 97.1% | 97.5% | 86.8% | - | 0 |
Schoepfer et al[22] | 36 | 28 | Adults | SES-CD; Rachmilewitz | ≤ 19; ≤ 4 | 50 | - | - | - | - | - | < 0.0001 |
Canani et al[50] | 26 | 32 | Paediatrics | Saverymuttu | ≤ 1 | 143 | - | - | - | - | 0.46% | ≤ 0.05 |
Fagerberg et al[31] | 27 | 10 | Paediatrics | Saverymuttu | < 85.7 | - | - | - | - | 0.65% | < 0.001 | |
Silberer et al[32] | 21 | 18 | Adults | Stange | 18.6 | 61.5% | 95% | - | - | - | < 0.0001 | |
Røseth et al[33] | 17 | 28 | Adults | Farup | < 50 | 0% | 100% | - | 97.8% | - | - | |
Bunn et al[34] | 2 | 9 | Paediatrics | Saverymuttu | - | - | - | - | 0.65% | < 0.05 | ||
Ulcerative colitis studies | ||||||||||||
Falvey et al[46] | 38 | Adults | Baron | 0 | 125 | 74% | 80% | 85% | 67% | 0.55% | < 0.0001 | |
200 | 58% | 95% | 95% | 59% | ||||||||
Nancey et al[45] | 55 | Adults | Rachmilewitz | ≤ 2 | 250 | 91% | 87% | 87% | 91% | 0.75% | < 0.0001 | |
100 | 100% | 53% | 85% | 100% | ||||||||
Kristensen et al[48] | 62 | Adults | Mayo | 0 | 61 Cal | 84.1% | 83.3% | 92.5% | 68.2% | < 0.001 | ||
0 | 96 BM | 90.9% | 83.3% | 93% | 78.9% | < 0.001 | ||||||
≤ 1 | 110 Cal | 80% | 66.6% | 69.2% | 78% | |||||||
≤ 1 | 259 BM | 83.3% | 71.9% | 73.5% | 82.1% | |||||||
D’Haens et al[47] | 39 | Adults | Mayo | 0 | < 250 | 71% | 100% | 100% | 47.1% | 0.56% | < 0.001 | |
Komraus et al[35] | 16 | Paediatrics | Rachmilewitz | < 50 | - | - | - | - | 0.52% | 0.0391 | ||
Aomatsu et al[16] | 17 | Paediatrics | Matts | ≤ 6 | 100 | 94.1% | 50% | 88.9% | 66.7% | 0.84% | < 0.01 | |
150 | 91.2% | 87.5% | 96.9% | 70% | ||||||||
Schoepfer et al[27] | 115 | Adults | Rachmilewitz | < 4 | < 50 | 93% | 71% | 91% | 81% | 0.83% | < 0.001 | |
< 100 | 86% | 88% | 96% | 65% | ||||||||
Langhorst et al[23] | 42 | Adults | Mayo | > 6 | 100% | 6.7% | 6.6% | 100% | 0.49% | < 0.001 | ||
> 48 | 81.5% | 72.3% | 84.6% | 68.8% | ||||||||
Schoepfer et al[22] | 28 | Adults | Rachmilewitz | ≤ 4 | 50 | - | - | - | - | - | 0.0025 | |
Schoepfer et al[26] | 12 | Adults | Rachmilewitz | ≤ 1 | < 50 | - | - | - | - | - | 0.0335 | |
D'Incà et al[28] | 46 | Adults | Mayo | > 80 | - | - | - | - | 0.511% | 0.001 | ||
Hanai et al[36] | 31 | Adults | Matts | ≤ 1 | - | - | - | - | 0.81% | < 0.001 | ||
Røseth et al[37] | 62 | Adults | Sandborn | ≤ 1 | < 10 | - | 34% | - | - | 0.57% | < 0.0001 | |
< 20 | - | 62% | - | - |
Table 2 Studies investigating the correlation between faecal lactoferrin concentrations and endoscopic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Endoscopic index used | Endoscopic indexcut off | Faecal lactoferrincut off (μg/mL) | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | |||||
Crohn’s disease studies | ||||||||||||
Sipponen et al[17] | 19 | Adults | SES-CD | ≤ 2 | < 7.25 | - | 80% | - | - | - | - | |
Pfefferkorn et al[38] | 54 | Paediatrics | Unique score | ≥ 7.25 | 100% | 43% | 70% | 100% | - | < 0.001 | ||
≥ 60 | 84% | 74% | 81% | 77% | ||||||||
Sipponen et al[18] | 61 | Adults | SES-CD (total) | ≤ 3 | < 7.25 | - | - | - | - | 0.705% | < 0.001 | |
SES-CD (colon) | ≤ 3 | < 7.25 | - | - | - | - | 0.627% | < 0.001 | ||||
SES-CD (ileal) | ≤ 3 | < 7.25 | - | - | - | - | 0.18% | > 0.05 | ||||
Sipponen et al[19] | 15 | Adults | CDEIS | ≤ 2 | < 10 | 77% | 100% | 100% | 58% | 0.865% | < 0.001 | |
Sipponen et al[20] | 77 | Adults | CDEIS | ≤ 2 | < 10 | 66% | 92% | 94% | 59% | 0.773% | < 0.001 | |
< 7.25 | 71% | 83% | 89% | 60% | ||||||||
Jones et al[24] | 164 | Adults | SES-CD | ≤ 6 | < 7.25 | - | - | - | - | 0.48% | < 0.05 | |
Langhorst et al[23] | 43 | Adults | SES-CD | > 7.25 | 81.8% | 60% | 87.1% | 50% | 0.42% | < 0.01 | ||
> 7.05 | 81.8% | 60% | 87.1% | 50% | ||||||||
Schoepfer et al[22] | 36 | Adults | SES-CD | ≤ 19 | 7 | - | - | - | - | - | < 0.0001 | |
Schoepfer et al[26] | 24 | Adults | SES-CD | ≤ 19 | < 7 | - | - | - | - | - | 0.0008 | |
D'Incà et al[28] | 31 | Adults | SES-CD | - | - | - | - | 0.192% | 0.545 | |||
Mixed inflammatory bowel disease population studies | ||||||||||||
Vieira et al[30] | 38 | 40 | Adults | CDEIS; Mayo | ≤ 2; ≤ 2 | 4-8 | 93.2% | 76.5% | 83.7% | 89.7% | - | 0 |
Schoepfer et al[22] | 36 | 28 | Adults | SES-CD; Rachmilewitz | ≤ 19; ≤ 4 | 7 | - | - | - | - | - | < 0.0001 |
Silberer et al[32] | 21 | 18 | Adults | Stange | 6.64 | 33.3% | 95% | - | - | - | 0.0059 | |
Ulcerative colitis studies | ||||||||||||
Langhorst et al[23] | 42 | Adults | Mayo | > 7.25 | 88.9% | 66.7% | 82.8% | 76.9% | 0.56% | < 0.001 | ||
> 7.05 | 92.6% | 66.7% | 83.3% | 83.3% | ||||||||
Schoepfer et al[22] | 28 | Adults | Rachmilewitz | ≤ 4 | 7 | - | - | - | - | - | 0.078 | |
Schoepfer et al[26] | 12 | Adults | Rachmilewitz | ≤ grade 1 | < 7 | - | - | - | - | - | 0.7815 | |
D'Incà et al[28] | 46 | Adults | Mayo | - | - | - | - | 0.354% | 0.023 |
Table 3 Studies investigating the correlation between other faecal marker concentrations and endoscopic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Endoscopic index used | Endoscopic indexcut off | Faecal marker measured | Faecal marker cut off | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | ||||||
Nancey et al[45] | 78 | Adults | SES-CD | ≤ 2 | Neopterin | 200 pmol/g | 74 | 73 | 73 | 74 | 0.47 | < 0.001 | |
150 pmol/g | 80 | 65 | 68 | 78 | |||||||||
55 | Adults | Rachmilewitz | ≤ 2 | Neopterin | 200 pmol/g | 74 | 100 | 100 | 73 | 0.72 | < 0.001 | ||
150 pmol/g | 84 | 100 | 100 | 78 | |||||||||
Nakarai et al[39] | 152 | Mixed | Mayo | 0 | Faecal Hb | < 100 ng/mL | 92 | 71 | 37 | 97 | 0.5409 | < 0.0001 | |
Faecal Hb | < 60 ng/mL | 94 | 74 | 40 | 98 | ||||||||
Mayo | ≤ 1 | Faecal Hb | < 100 ng/mL | 60 | 87 | 85 | 64 | ||||||
Faecal Hb | < 60 ng/mL | 58 | 90 | 88 | 64 | ||||||||
Langhorst et al[23] | 43 | Adults | SES-CD | PMN-e | < 0.062 μg/mL | 81.8 | 70 | 90 | 54.8 | 0.32 | < 0.05 | ||
42 | Adults | Mayo | PMN-e | < 0.062 μg/mL | 70.4 | 66.7 | 79.2 | 55.6 | 0.36 | < 0.05 | |||
Silberer et al[32] | 21 | 18 | Adults | Stange | PMN-e | 0.124 | 79.5 | 95 | - | - | - | < 0.0001 | |
Lysozyme | 1.3 | 47.5 | 95 | - | - | - | < 0.0001 | ||||||
α1-AT | 158 | 20 | 95 | - | - | - | - | ||||||
Faecal Hb | 1.8 | 61.5 | 95 | - | - | - | - | ||||||
Hb-Hp | 0.8 | 64.1 | 95 | - | - | - | - | ||||||
Moran et al[40] | 7 | 21 | Mixed | Farmer | α1-AT | ≤ 0.58 mg/g | - | - | - | - | 0.83 | 0.001 | |
Cellier et al[41] | 95 | Adults | CDEIS | α1-AT | - | - | - | - | 0.26 | 0.001 |
Table 4 Studies investigating the correlation between FC concentrations and histologic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Histology index used | Histology indexcut off | Faecal calprotectincut off (μg/g) | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | |||||
Crohn’s disease studies | ||||||||||||
Sipponen et al[18] | 61 | Adult | D'Haens (ileocolonic) | < 100 | - | - | - | - | 0.563 | < 0.01 | ||
D'Haens (ileal) | < 100 | - | - | - | - | 0.311 | > 0.05 | |||||
Sipponen et al[19] | 15 | Adult | D'Haens (pretreatment colonic) | < 200 | - | - | - | - | 0.522 | 0.046 | ||
D'Haens (posttreatment colonic) | < 200 | - | - | - | - | - | > 0.05 | |||||
D'Haens (ileal) | < 200 | - | - | - | - | - | > 0.05 | |||||
Canani et al[50] | 26 | Paediatric | Saverymuttu | ≤ 1 | 143 | - | - | - | - | 0.681 | < 0.0001 | |
Kaiser et al[42] | 32 | Adult | Unique score | 0 | < 50 | - | - | - | - | 0.412 | < 0.05 | |
D'Incà et al[28] | 31 | Adult | Fazio | > 80 | 81% | 80% | 95% | - | 0.117 | 0.545 | ||
Fagerberg et al[43] | 22 | Paediatric | Unique score | < 50 | 95% | 93% | 95% | 93% | - | < 0.00001 | ||
Mixed inflammatory bowel disease population studies | ||||||||||||
Vieira et al[30] | 38 | 40 | Adult | Unique score | > 200 | 77% | 100% | 100% | 68% | - | 0 | |
Canani et al[50] | 26 | 32 | Paediatric | Saverymuttu | ≤ 1 | 143 | 94% | 64% | 81% | 87% | 0.655 | < 0.05 |
D'Incà et al[28] | 31 | 46 | Adult | Fazio; Floren (SES-CD; Mayo) | > 80 | 79 | 74% | 92% | - | - | - | |
Fagerberg et al[31] | 27 | 10 | Paediatric | Saverymuttu | ≤ 2 | < 50 | 93% | 73% | 90% | 80% | 0.75 | < 0.001 |
< 85.7 | 93% | 82% | 93% | 82% | ||||||||
Saverymuttu | - | - | - | - | 0.79 | < 0.001 | ||||||
Kolho et al[44] | 9 | 16 | Paediatric | Farup | 50 | - | - | 69% | 100% | - | - | |
100 | - | - | 72% | 96% | - | - | ||||||
Bunn et al[53] | 2 | 9 | Paediatric | Saverymuttu | ≤ 6 | 6.3 | 100% | 80% | - | - | 0.74 | < 0.01 |
Ulcerative colitis studies | ||||||||||||
Canani et al[50] | 32 | Paediatric | Saverymuttu | ≤ 1 | 143 | - | - | - | - | 0.661 | < 0.0001 | |
D'Incà et al[28] | 46 | Adult | Floren | > 80 | 78% | 70% | 90% | - | 0.323 | 0.042 | ||
Kaiser et al[42] | 27 | Adult | Unique score | < 50 | - | - | - | - | 0.311 | 0.14 | ||
Røseth et al[37] | 62 | Adult | Farup | ≤ 1 | < 10 | - | 50% | - | - | 0.70 | < 0.0001 | |
< 20 | - | 81% | - | - |
Table 5 Studies investigating the correlation between faecal lactoferrin concentrations and histologic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Histology index used | Histology indexcut off | Faecal lactoferrincut off(μg/mL) | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | |||||
Crohn’s disease studies | ||||||||||||
Sipponen et al[18] | 61 | Adults | D'Haens (ileocolonic) | < 7.25 | - | - | - | - | 0.543 | < 0.01 | ||
D'Haens (ileal) | < 7.25 | - | - | - | - | 0.291 | > 0.05 | |||||
Sipponen et al[19] | 15 | Adult | D'Haens (pretreatment colonic) | < 10 | - | - | - | - | 0.482 | 0.069 | ||
D'Haens (posttreatment colonic) | < 10 | - | - | - | - | - | > 0.05 | |||||
D'Haens (ileal) | < 10 | - | - | - | - | - | > 0.05 | |||||
D'Incà et al[28] | 31 | Adult | Fazio | 77% | 80% | 95% | - | 0.477 | 0.009 | |||
Mixed inflammatory bowel disease studies | ||||||||||||
Vieira et al[30] | 38 | 40 | Adults | Unique score | 4-8 | 90% | 92% | 96% | 83% | - | - | |
D'Incà et al[28] | 31 | 46 | Adults | Fazio; Floren (SES-CD; Mayo) | 7 | 76% | 67% | 90% | - | - | - | |
Ulcerative colitis studies | ||||||||||||
D'Incà et al[28] | 46 | Adults | Floren | 7 | 75% | 60% | 87% | 92% | 0.544 | 0.0001 |
Table 6 Studies investigating the correlation between other faecal marker concentrations and histologic activity in subjects with inflammatory bowel diseases
Ref. | Number of participants | Population | Histology index used | Histology indexcut off | Faecal marker measured | Faecal marker cut off | Outcome measures | Correlation | |||||
CD | UC | Sensitivity | Specificity | PPV | NPV | r value | P value | ||||||
Crohn’s disease studies | |||||||||||||
Kaiser et al[42] | 32 | 27 | Adults | Unique score | 0 | S100A12 | - | - | - | - | 0.44 | < 0.01 | |
32 | S100A12 | 0.8 | 81 | 100 | - | - | 0.451 | 0.01 | |||||
27 | S100A12 | 0.8 | 91 | 100 | - | - | 0.44 | < 0.025 |
- Citation: Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480
- URL: https://www.wjgnet.com/1007-9327/full/v21/i40/11469.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i40.11469